Jan 3rd, 2024
Obesity Drugs: Global Sales Could Hit $80 Billion in 2030
Like in diabetes, Novo Nordisk and Eli Lilly compete in the obesity market where global sales could hit $80 billion in 2030. Lilly’s newcomer Zepbound could become a big rival to Novo’s Wegovy and Ozempic drugs. But some like Astrazeneca, Roche, and others including Altimmune, Zealand and Amgen are also entering the market. Bloomberg Intelligence's Sam Fazeli explains.
